Casa
asdas

A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).

Por um escritor misterioso

Descrição
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. - Abstract - Europe PMC
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
TNF Inhibitor Therapy, Ankylosing Spondylitis
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice – topic of
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
IJMS, Free Full-Text
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex, Arthritis Research & Therapy
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Full article: POSTER PRESENTATIONS
A. Mean ASDAS and B. mean BASDAI to week 96. Safety set (N = 89).
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study - Pavelka - 2020 - ACR Open Rheumatology - Wiley Online Library
de por adulto (o preço varia de acordo com o tamanho do grupo)